The Concord Biotech IPO commenced on August 4, 2023, and concluded on August 8, 2023. The allotment of shares took place on August 11, 2023, and the initiation of refunds began on August 14, 2023. The shares were credited to the demat accounts of investors on August 17, 2023. Finally, the listing of Concord Biotech on the stock exchange occurred on August 18, 2023.
The Concord Biotech IPO was priced at ₹00 per share, with a lot size of 00. The total issue size was ₹00 crores, comprising a fresh issue of ₹00 crores and an offer for sale of ₹00 crores. The IPO was listed on both the NSE and BSE.
In terms of quota reservations, the QIB (Qualified Institutional Buyers) quota was reserved for 50% of the shares, the NII (Non-Institutional Investors) quota was reserved for 15% of the shares, and the retail quota was reserved for 35% of the shares.
Concord Biotech IPO Basic Details
| Company Name | Concord Biotech Limited |
| Domain of Company | Indian Biopharmaceutical Company |
| Concord Biotech IPO GMP Today | ₹185 |
| Concord Biotech IPO Listing Gain | 24.97% |
| Concord Biotech IPO Open Date | August 4, 2023 |
| Concord Biotech IPO Close Date | August 8, 2023 |
| Concord Biotech IPO Allotment Date | August 11, 2023 |
| Concord Biotech IPO Listing Date | August 18, 2023 |
| Face Value | ₹10 per share |
| Price | ₹705 to ₹741 per share |
| Lot Size | 20 Shares |
| Issue Size | 20,925,652 shares (aggregating up to ₹1,551.00 Cr) |
| Offer for Sale | 20,925,652 shares (aggregating up to ₹1,551.00 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE, BSE |
| Company Promoters | Sudhir Vaid And Ankur Vaid |
Concord Biotech IPO GMP Today:
| Date | GMP | Listing Gain | Kostak | Subject to |
| 16 August 2023 | ₹122 | 16.46% | – | – |
| 15 August 2023 | ₹122 | 16.46% | – | – |
| 14 August 2023 | ₹122 | 16.46% | – | – |
| 13 August 2023 | ₹122 | 16.46% | – | – |
| 12 August 2023 | ₹122 | 16.46% | – | – |
| 11 August 2023 | ₹122 | 16.46% | – | – |
| 10 August 2023 | ₹122 | 16.46% | – | – |
| 9 August 2023 | ₹122 | 16.46% | – | – |
| 8 August 2023 | ₹122 | 16.46% | – | – |
| 7 August 2023 | ₹122 | 16.46% | – | – |
| 6 August 2023 | ₹122 | 16.46% | – | – |
| 5 August 2023 | ₹122 | 16.46% | – | – |
| 4 August 2023 | ₹188 | 25.37% | – | – |
| 3 August 2023 | ₹185 | 24.97% | – | – |
| 2 August 2023 | ₹185 | 24.97% | – | – |
Concord Biotech IPO Details:
Established in 1984, Concord Biotech Limited is an Indian biopharmaceutical company driven by research and development. It has earned a prominent position as a global leader in the development and production of fermentation-based Active Pharmaceutical Ingredients (APIs) for immunosuppressants and oncology, based on market share by volume in 2022.
Concord Biotech operates internationally, supplying its products to more than 70 countries, including the USA, India, Europe, and Japan.
The company specializes in manufacturing APIs through fermentation and semi-synthetic processes, as well as finished formulations. What began with a single product has now expanded into a diverse range of solutions, catering to various therapeutic segments.
Concord’s product portfolio includes fermentation and semi-synthetic-based offerings in areas like Immunosuppressants, Anti-bacterial, Oncology, Antifungals, and others, which have garnered a strong customer base worldwide. Additionally, the company maintains an active pipeline of products under development.
Concord Biotech IPO More Details Click Here
Yatharth Hospital IPO FAQs
When is Concord Biotech IPO open?
Concord Biotech IPO will open on 4 August 2023.
When is Concord Biotech IPO Close?
Concord Biotech IPO will be closed on 8 August 2023.
What is Concord Biotech IPO GMP Today?
The Concord Biotech IPO GMP aka Grey Market Premium is ₹122.
What is Concord Biotech IPO Kostak Rates Today?
The Concord Biotech IPO Kostak Rate is ₹000.
What is Concord Biotech IPO Subject to Sauda Price Today?
The Nimbark IPO subject to sauda rates is ₹000.
Concord Biotech IPO Expected Returns?
The Concord Biotech expected return is 16.46%.
How much will be the listing gain in Concord Biotech IPO?
Concord Biotech IPO will get listing gain of 16.46%. (Approx.)
